专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011130417A3 HUMAN FGF RECEPTOR AND ß-KLOTHO BINDING PROTEINS 审中-公开
标题翻译：人FGF受体和ß-KLOTHO结合蛋白
公开(公告)号：WO2011130417A3
公开(公告)日：2012-03-08
申请号：PCT/US2011032333
申请日：2011-04-13
申请人： AMGEN INC , FACHINI ROGER , FOLTZ IAN , HAN SEOG JOON , HARRIS SUSIE MIKI , HU SHAW-FEN SYLVIA , KING CHADWICK TERENCE , LI YANG , LU JI , MICHAELS MARK LEO , SUN JEONGHOON
发明人： FACHINI ROGER , FOLTZ IAN , HAN SEOG JOON , HARRIS SUSIE MIKI , HU SHAW-FEN SYLVIA , KING CHADWICK TERENCE , LI YANG , LU JI , MICHAELS MARK LEO , SUN JEONGHOON
IPC分类号： C07K16/28 , A61K39/395 , A61P3/10
CPC分类号： A61K39/3955 , C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/32 , C07K2317/75 , C07K2317/92 , C07K2319/75
摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to ß-Klotho, or ß-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to ß-Klotho, or ß-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
摘要翻译：本发明提供与抗原结合蛋白和特异性结合ß-Klotho或ß-Klotho以及FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种的抗原结合蛋白和抗原结合蛋白-FGF21融合物相关或衍生的组合物和方法。在一些实施方案中，抗原结合蛋白和抗原结合蛋白FGF21融合物诱导FGF21样信号传导。在一些实施方案中，抗原结合蛋白或抗原结合蛋白-FGF21融合抗原结合组分是完全人，人源化或嵌合抗体，这种抗体的结合片段和衍生物，以及特异性结合ß-Klotho或ß- Klotho和FGFR1c，FGFR2c，FGFR3c和FGFR4中的一种或多种。其他实施方案提供编码这种抗原结合蛋白和抗原结合蛋白-FGF21融合体的核酸，及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备这种抗原结合蛋白的方法和抗原结合蛋白-FGF21融合物，其衍生物和多肽，以及使用这种抗原结合蛋白和抗原结合蛋白-FGF21融合体，其片段和衍生物和多肽的方法，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症。

2. 发明申请

WO2012170438A2 HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING ß-KLOTHO AND AN FGF RECEPTOR 审中-公开
标题翻译：包含ß-KLOTHO和FGF受体的复合物的人抗原结合蛋白
公开(公告)号：WO2012170438A2
公开(公告)日：2012-12-13
申请号：PCT/US2012040941
申请日：2012-06-05
申请人： AMGEN INC , LI YANG , STEVENS JENNITTE , KING CHADWICK TERENCE , FOLTZ IAN , KANNAN GUNASEKARAN , YIE JUNMING , HU SHAW-FEN SYLVIA
发明人： LI YANG , STEVENS JENNITTE , KING CHADWICK TERENCE , FOLTZ IAN , KANNAN GUNASEKARAN , YIE JUNMING , HU SHAW-FEN SYLVIA
IPC分类号： A61K39/00
CPC分类号： C07K16/2863 , A61K2039/505 , C07K14/71 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2319/00 , C07K2319/30 , C12Y302/01031
摘要： The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising ß-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to a complex comprising ß-Klotho and at least one of (i) FGFR1c, (ii) FGFR2c and (iii) FGFR3c. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
摘要翻译：本发明提供与能够诱导B-Klotho和/或FGF21样介导的信号传导的抗原结合蛋白相关或衍生的组合物和方法。在实施方案中，抗原结合蛋白特异性结合包含β-Klotho和（i）FGFR1c，（ii）FGFR2c和（iii）FGFR3c中的至少一种的复合物。在一些实施方案中，抗原结合蛋白诱导FGF21样信号传导。在一些实施方案中，抗原结合蛋白是完全人，人源化或嵌合抗体，所述抗体的结合片段和衍生物，以及特异性结合包含β-Klotho和（i）FGFR1c，（ ii）FGFR2c和（iii）FGFR3c。其它实施方案提供了编码这种抗原结合蛋白的核酸及其片段和衍生物，以及多肽，包含这种多核苷酸的细胞，制备此类抗原结合蛋白的方法及其片段和衍生物以及多肽，以及使用这种抗原结合蛋白的方法，其片段及其衍生物和多肽，包括治疗或诊断患有2型糖尿病，肥胖症，NASH，代谢综合征和相关疾病或病症的受试者的方法。

3. 发明申请

WO2008036341A2 COMPOSITIONS AND METHODS RELATING TO GLUCAGON RECEPTOR ANTIBODIES 审中-公开
标题翻译：与GLUCAGON受体抗体相关的组合物和方法
公开(公告)号：WO2008036341A2
公开(公告)日：2008-03-27
申请号：PCT/US2007020349
申请日：2007-09-19
申请人： AMGEN INC , YAN HAI , HU SHAW-FEN SYLVIA , BOONE THOMAS C , LINDBERG RICHARD A
发明人： YAN HAI , HU SHAW-FEN SYLVIA , BOONE THOMAS C , LINDBERG RICHARD A
CPC分类号： C07K16/2869 , A61K2039/505 , C07K14/723 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies which specifically bind to the human glucagon receptor. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies including methods of treating and preventing type 2 diabetes and related disorders by administering such antibodies to a subject in need of such treatment.
摘要翻译：本公开提供了与抗原结合蛋白特别是特异性结合人胰高血糖素受体的抗体相关的组合物和方法。本公开提供了编码这种抗原结合蛋白的核酸和抗体，以及制备和使用这些抗体的方法，包括通过向需要这种治疗的受试者施用此类抗体来治疗和预防2型糖尿病和相关疾病的方法。

4. 发明申请

WO2007092640A2 ANTIBODIES THAT BIND PAR-2 审中-公开
标题翻译： BIND PAR-2的抗体
公开(公告)号：WO2007092640A2
公开(公告)日：2007-08-16
申请号：PCT/US2007003796
申请日：2007-02-09
申请人： AMGEN INC , VIRCA GEORGE DUKE , HU SHAW-FEN SYLVIA
发明人： VIRCA GEORGE DUKE , HU SHAW-FEN SYLVIA
CPC分类号： C07K16/28 , A61K2039/505 , C07K2317/34 , C07K2317/76 , C07K2317/92
摘要： The present invention provides compositions and methods relating to or derived from anti-PAR-2 antibodies. In particular embodiments, the invention provides antibodies that bind human PAR-2, PAR-2-binding fragments and derivatives of such antibodies, and PAR-2-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PAR-2-related disorders or conditions.
摘要翻译：本发明提供了与抗PAR-2抗体有关或衍生自抗PAR-2抗体的组合物和方法。在具体实施方案中，本发明提供了结合人PAR-2，PAR-2-结合片段和此类抗体衍生物的抗体，以及包含此类片段的PAR-2结合多肽。其它实施方案提供编码此类抗体，抗体片段和衍生物和多肽的核酸，包含此类多核苷酸的细胞，制备此类抗体的方法，抗体片段和衍生物和多肽，以及使用此类抗体，抗体片段和衍生物和多肽的方法，包括方法治疗或诊断患有PAR-2相关疾病或病症的受试者。

5. 发明申请

WO2008088422A3 TOXIN PEPTIDE THERAPEUTIC AGENTS 审中-公开
标题翻译：毒素代谢治疗药物
公开(公告)号：WO2008088422A3
公开(公告)日：2009-02-19
申请号：PCT/US2007022831
申请日：2007-10-25
申请人： AMGEN INC , SULLIVAN JOHN K , MCGIVERN JOSEPH G , MIRANDA LESLIE P , NGUYEN HUNG Q , WALKER KENNETH W , HU SHAW-FEN SYLVIA , GEGG COLIN V JR , ARORA KHARE TARUNA , ADLER BEVERLY S , MARTIN FRANCIS H
发明人： SULLIVAN JOHN K , MCGIVERN JOSEPH G , MIRANDA LESLIE P , NGUYEN HUNG Q , WALKER KENNETH W , HU SHAW-FEN SYLVIA , GEGG COLIN V JR , ARORA KHARE TARUNA , ADLER BEVERLY S , MARTIN FRANCIS H
IPC分类号： A61K47/48 , A61K38/16 , A61P37/06 , C07K14/435 , C12N15/62
CPC分类号： C07K14/43522 , A61K38/00 , A61K47/60 , C07K2319/30 , C07K2319/31
摘要： Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
摘要翻译：公开了包含OSK1肽类似物的物质组合物，并且在一些实施方案中为其药学上可接受的盐。药物组合物包含该组合物和药学上可接受的载体。还公开了编码本发明组合物的DNA，包含DNA的表达载体和包含表达载体的宿主细胞。还公开了治疗自身免疫性疾病和预防或减轻多发性硬化症状的复发的方法。

6. 发明申请

WO2010108154A3 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3 审中-公开
标题翻译： KV1.3的选择和磷酸肽抑制剂
公开(公告)号：WO2010108154A3
公开(公告)日：2011-03-03
申请号：PCT/US2010028061
申请日：2010-03-19
申请人： AMGEN INC , SULLIVAN JOHN K , MIRANDA LESLIE P , GEGG COLIN V , HU SHAW-FEN SYLVIA , BELOUSKI EDWARD J , MURRAY JUSTIN K , NGUYEN HUNG , WALKER KENNETH W , ARORA TARUNA , JACOBSEN FREDERICK W , LI YUE-SHENG , BOONE THOMAS C
发明人： SULLIVAN JOHN K , MIRANDA LESLIE P , GEGG COLIN V , HU SHAW-FEN SYLVIA , BELOUSKI EDWARD J , MURRAY JUSTIN K , NGUYEN HUNG , WALKER KENNETH W , ARORA TARUNA , JACOBSEN FREDERICK W , LI YUE-SHENG , BOONE THOMAS C
IPC分类号： A61K38/00
CPC分类号： C07K16/44 , A61K39/39591 , A61K47/6817 , A61K47/6843 , C07K14/43504 , C07K14/575 , C07K14/605 , C07K14/66 , C07K16/00 , C07K16/18 , C07K16/248 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/55
摘要： Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.
摘要翻译：公开了具有SEQ ID NO：4的氨基酸序列或其药学上可接受的盐的物质组合物，包括包含与ShK，HmK和AETX-K相关的毒素肽类似物的实施方案，以及含有它们的药物组合物或药物以及药学上可接受的载体。一些实施方案包括半衰期延长部分。还公开了预防或减轻多发性硬化症状的复发的方法以及使用该组合物治疗自身免疫病症的方法。

7. 发明申请

WO2006116156A3 TOXIN PEPTIDES WITH EXTENDED BLOOD HALFLIFE 审中-公开
标题翻译：具有扩张性血液活化的毒素肽
公开(公告)号：WO2006116156A3
公开(公告)日：2007-10-04
申请号：PCT/US2006015199
申请日：2006-04-18
申请人： AMGEN INC
发明人： SULLIVAN JOHN K , MCGIVERN JOSEPH G , MIRANDA LESLIE P , NGUYEN HUNG Q , WALKER KENNETH W , HU SHAW-FEN SYLVIA , GEGG JR COLIN V , MCDONOUGH STEFAN I
IPC分类号： A61K47/48 , A61K38/16 , A61P37/06 , C07K14/435 , C12N15/62
CPC分类号： A61K47/48215 , A61K38/00 , A61K47/60 , C07K14/43504 , C07K2319/30 , C07K2319/55
摘要： Disclosed is a composition of matter of the formula (I) (X 1 ) a -(F 1 ) d -(X 2 ) b -(F 2 ) e -(X 3 ) c and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X 1 , X 2 , and X 3 are each independently -(L) f -P-(L) g -, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, obesity, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.
摘要翻译：公开了式（I）（X 1）的物质组合物（X 1） > - （X ^{2 ）_{b'/ SUB> - （F ^{2 ）_{ë - （X ³}}}}

8. 发明公开

EP2432488A4 SELECTIVE AND POTENT PEPTIDE INHIBITORS OF KV1.3 审中-公开
标题翻译：。TIVE。。H ON ON ON ON ON ON ON ON ON。
公开(公告)号：EP2432488A4
公开(公告)日：2014-01-08
申请号：EP10754211
申请日：2010-03-19
申请人： AMGEN INC
发明人： SULLIVAN JOHN K , MIRANDA LESLIE P , GEGG COLIN V , HU SHAW-FEN SYLVIA , BELOUSKI EDWARD J , MURRAY JUSTIN K , NGUYEN HUNG , WALKER KENNETH W , ARORA TARUNA , JACOBSEN FREDERICK W , LI YUE-SHENG , BOONE THOMAS C
IPC分类号： A61K38/16
CPC分类号： C07K16/44 , A61K39/39591 , A61K47/6817 , A61K47/6843 , C07K14/43504 , C07K14/575 , C07K14/605 , C07K14/66 , C07K16/00 , C07K16/18 , C07K16/248 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C07K2319/30 , C07K2319/55

9. 发明申请

WO2014151834A3 METHODS AND COMPOSITIONS RELATING TO ANTI-CCR7 ANTIGEN BINDING PROTEINS 审中-公开
标题翻译：与抗CCR7抗原结合蛋白相关的方法和组合物
公开(公告)号：WO2014151834A3
公开(公告)日：2014-12-04
申请号：PCT/US2014026537
申请日：2014-03-13
申请人： AMGEN INC
发明人： KING CHADWICK TERENCE , NG GORDON , HU SHAW-FEN SYLVIA , NGUYEN HUNG , JUNG JEANNIE
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K39/0005 , A61K2039/5156 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.
摘要翻译：本发明提供了涉及针对CCR7的抗原结合蛋白的组合物和方法，包括抗体，核酸，载体，制备抗原结合蛋白的方法，以及使用抗原结合蛋白的方法。

10. 发明申请

WO0009714A9 OVEREXPRESSION OF DESIRED PROTEINS IN EUKARYOTIC CELLS MEDIATED BY CYCLIN D1 OVEREXPRESSION 审中-公开
标题翻译： CYCLIN D1超表达介导的原核细胞中所需蛋白质的超表达
公开(公告)号：WO0009714A9
公开(公告)日：2000-05-18
申请号：PCT/US9918213
申请日：1999-08-11
申请人： AMGEN INC
发明人： HU SHAW-FEN SYLVIA , GUDAS JEAN MARIE , BRANKOW DAVID WILLIAM
IPC分类号： C12N15/09 , C07K14/47 , C07K14/475 , C12N5/10 , C12N15/67 , C12P21/02
CPC分类号： C07K14/4738 , C07K14/475 , C12N15/67
摘要： The invention concerns eukaryotic cells useful in protein expression comprising (a) an inserted nucleic acid encoding a cyclin D gene product and (b) an inserted nucleic acid encoding a protein of interest, wherein the cyclin D gene product and the protein of interest are expressed in the cell. The invention also concerns a process for producing a protein of interest, which comprises (a) inserting into a eukaryotic cell a nucleic acid encoding a cyclin D gene product and a nucleic acid encoding a protein of interest; (b) culturing the cell under conditions permitting the expression of the protein of interest; and (c) isolating the protein of interest. The cells are preferably mammalian, with CHO cells most preferred. The cyclin D gene product is preferably of human origin. Suitable proteins of interest include erythropoietin (EPO), osteoprotegerin (OPG), OPG-Fc, leptin, Fc-leptin, and Novel Erythropoiesis Stimulating Protein (NESP).
摘要翻译：本发明涉及可用于蛋白质表达的真核细胞，其包含（a）编码细胞周期蛋白D基因产物的插入核酸和（b）编码目的蛋白质的插入核酸，其中所述细胞周期蛋白D基因产物和目的蛋白质被表达在细胞中本发明还涉及产生感兴趣的蛋白质的方法，其包括（a）将真核细胞插入编码细胞周期蛋白D基因产物的核酸和编码感兴趣的蛋白质的核酸; （b）在允许感兴趣的蛋白质表达的条件下培养细胞; 和（c）分离感兴趣的蛋白质。细胞优选是哺乳动物，最优选CHO细胞。细胞周期蛋白D基因产物优选来源于人。合适的目标蛋白包括促红细胞生成素（EPO），骨保护素（OPG），OPG-Fc，瘦蛋白，Fc-瘦蛋白和新型红细胞生成刺激蛋白（NESP）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式